HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

DNA flow cytometric analysis of chest-wall chondroma and chondrosarcoma.

Abstract
DNA flow cytometric analysis was performed for prediction of malignancy potential, and hence of outcome, in 17 patients aged 29-76 (mean 52) years with cartilaginous tumour of the chest wall. Histologically there were nine chondromas and eight chondrosarcomas. The chondrosarcomas (3 grade I, 4 grade II, 1 grade III) were significantly larger than the chondromas (13.6 +/- 7.8 vs 4.2 +/- 2.0 cm, p < 0.001). DNA flow cytometry was performed on paraffin-embedded blocks of resected tumour. In eight of the 17 tumours (6 chondromas, 1 grade I and 1 grade II chondrosarcoma) measurement of DNA content failed because of low cellularity and severe calcification. Aneuploid DNA content was detected only in three chondrosarcomas (2 grade II, 1 grade III). The synthetic phase fraction was less than 15% in all the studied chondromas, but exceeded 25% in four of six chondrosarcomas. This case series though small, may indicate a trend towards association between higher histologic grading and greater incidence of aneuploidy with higher synthetic phase fraction. Tumour size, histologic grade, DNA ploidy and adequacy of surgical resection are the main influences on prognosis.
AuthorsC S Shih, L S Wang, S S Yang, H J Fahn, L H Wu, W Y Chen, M H Huang
JournalScandinavian journal of thoracic and cardiovascular surgery (Scand J Thorac Cardiovasc Surg) Vol. 30 Issue 3-4 Pg. 157-61 ( 1996) ISSN: 0036-5580 [Print] Sweden
PMID8976036 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • DNA, Neoplasm
Topics
  • Adult
  • Aged
  • Bone Neoplasms (genetics, pathology)
  • Chondroma (genetics, pathology)
  • Chondrosarcoma (genetics, pathology)
  • DNA, Neoplasm (analysis)
  • Female
  • Flow Cytometry
  • Humans
  • Male
  • Middle Aged
  • Ribs
  • Sternum

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: